ロード中...
A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18–55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label ex...
保存先:
| 出版年: | J Clin Psychopharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Lippincott Williams & Wilkins
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5400413/ https://ncbi.nlm.nih.gov/pubmed/28383364 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000702 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|